Status:
COMPLETED
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Adenocarcinoma of the Lung
Adenosquamous Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This randomized phase II trial is studying how well giving docetaxel together with either cetuximab or bortezomib works as first-line therapy in treating patients with stage III or stage IV non-small ...
Detailed Description
PRIMARY OBJECTIVES: I. To evaluate the progression free survival (PFS), defined as the time between study entry and disease progression or death, for each of the two combination regimens. SECONDARY ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All patients must have histologically or cytologically documented non-small cell carcinoma of the lung (adenocarcinoma, large cell, squamous, or mixtures of these types)
- Patients with stage IV disease are eligible
- Patients with stage IIIB due to a malignant pleural effusion or supraclavicular node involvement are eligible (IIIB patients eligible for CALGB protocols of combined chemotherapy and thoracic radiotherapy are not eligible)
- Patients with known CNS metastases who have received therapy (surgery, XRT, gamma knife), and are neurologically stable and off steroids by the time of enrollment are eligible if they are not on enzyme-inducing anticonvulsants; patients with leptomeningeal disease are not eligible
- Documentation of PS 2 must be noted on form C-1392
- Patients must have measurable or non-measurable disease
- Measurable disease (target lesions): lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan
- Non-measurable disease (non-target lesions): all other lesions, including small lesions (longest diameter \< 20 mm with conventional techniques or \< 10 mm with spiral CT scan) and truly nonmeasurable lesions; lesions that are considered non-measurable include the following:
- Bone lesions
- Ascites
- Pleural/pericardial effusion
- Lymphangitis cutis/pulmonis
- Abdominal masses that are not confirmed and followed by imaging techniques
- Cystic lesions
- No prior systemic treatment for advanced NSCLC is permitted; prior treatment for early-stage disease (adjuvant) or for locally-advanced stage III disease is allowed if completed at least 12 months prior to registration
- Patients must have recovered (all toxicities ≤ grade 1) from prior surgery and/or radiotherapy
- No prior therapy which specifically and directly targets the EGFR pathway
- No prior severe infusion reactions to a monoclonal antibody
- No ≥ grade 2 peripheral neuropathy
- Non-pregnant and non-nursing
- No concurrent treatment with any other investigational therapy
- Granulocytes ≥ 1,500/μl
- Platelets ≥ 100,000/μl
- Serum creatinine ≤ ULN
- Bilirubin ≤ ULN
- AST ≤ ULN
Exclusion
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00118183
Start Date
July 1 2005
Last Update
June 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States, 33140